brief editorial new york times recent zyprexa scandal concludes lilly contends never promoted zyprexa unapproved uses always shown marketing materials food drug administration required law claims ought tested congressional hearings focus well industry complies existing laws effectively f regulates industry marketing materials sounds nice methinks bit naive prediction nothing worse slap wrist awaits lilly however sales zyprexa nearly certain suffer somewhere astrazeneca execs licking chops help sales seroquel may marketed anxiety depression alcoholism along bipolar schizophrenia long addition quite possible fda saw marketing materials nothing nobody seriously accused fda enforcing regulations advertising anything approaching barest amount rigor